Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes

Molecular Pharmacology

Volumn 75, Issue 4, 2009, Pages 762-773

  Pennington, M W ^a   Beeton, C ^b,c   Galea, C A ^d   Smith, B J ^d   Chi, V ^b   Monaghan, K P ^b   Garcia, A ^b   Rangaraju, S ^b   Giuffrida, A ^a   Plank, D ^a   Crossley, G ^a   Nugent, D ^a   Khaytin, I ^a   Lefievre, Y ^a   Peshenko, I ^a   Dixon, C ^a   Chauhan, S ^a   Orzel, A ^a   Inoue, T ^c   Hu, X ^c   Moore, R V ^c   Norton, R S ^d   Chandy, K G ^b   more..

^a Bachem Holding AG   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHOSPHONOPHENYLALANINE; DOCKING PROTEIN; PHENYLALANINE DERIVATIVE; PHOSPHOTYROSINE; PLANT TOXIN; POLYPEPTIDE; POLYPEPTIDE SHK 170; POLYPEPTIDE SHK 186; POLYPEPTIDE SHK 188; POLYPEPTIDE SHK 191; POLYPEPTIDE SHK 192; POTASSIUM CHANNEL KV1.3; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; AUTOIMMUNE DISEASE; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG HYDROLYSIS; DRUG OXIDATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STABILITY; EFFECTOR CELL; ELECTROPHYSIOLOGY; FEMALE; HIGH TEMPERATURE; HUMAN; HUMAN CELL; HYDROLYSIS; IC 50; INSULIN DEPENDENT DIABETES MELLITUS; LEWIS RAT; MEMORY T LYMPHOCYTE; MULTIPLE SCLEROSIS; NONHUMAN; OTITIS; OXIDATION; PH; PRIORITY JOURNAL; PROTEIN ENGINEERING; RAT; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

ANIMALS; CELL LINE; CERCOPITHECUS AETHIOPS; COS CELLS; FEMALE; HUMANS; KV1.3 POTASSIUM CHANNEL; PEPTIDES; POTASSIUM CHANNEL BLOCKERS; PROTEIN ENGINEERING; RATS; RATS, INBRED LEW; T-LYMPHOCYTES;

EID: 63849100894     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.052704     Document Type: Article

References (52)

1. Anfinsen CB and Corley LG (1969) An active variant of staphylococcal nuclease containing norleucine in place of methionine. J Biol Chem 244:5149-5152.
2. Azam P, Sankaranarayanan A, Homerick D, Griffey S, and Wulff H (2007) Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis. J Invest Dermatol 127:1419-1429.
3. Bartels C, Xia TH, Billeter M, Güntert P, and Wüthrich K (1995) The program XEASY for computer-supported NMR spectral analysis of biological macromole- cules. JBiomol NMR 6:1-10.
4. + channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. J Immunol 166:936-944.
5. Beeton C, Pennington MW, Wulff H, Singh S, Nugent D, Crossley G, Khaytin I, Calabresi PA, Chen CY, Gutman GA, et al. (2005) Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol 67:1369 -1381.
6. + channels and inhibits T lymphocyte proliferation. J Biol Chem 283:988-997.
7. + channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci USA 98:13942-13947.
8. Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington PW, Kolski-Andreaco A, Wei E, Grino A, Counts DR, et al. (2006) Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci USA 103:17414-17419.
9. + T cells reveals the existence of different memory T-cell subsets in the peripheral blood and liver. J Virol81:945-953.
10. Castaneda O, Sotolongo V, Amor AM, Stöcklin R, Anderson AJ, Harvey AL, Eng- ström Å, Wernstedt C, and Karlsson E (1995) Characterization of a potassium channel toxin from the Caribbean Sea anemone Stichodactyla helianthus. Toxicon 33:603-613.
11. Champagne P, Ogg GS, King AS, Knabenhans C, Ellefsen K, Nobile M, Appay V, Rizzardi GP, Fleury S, Lipp M, et al. (2001) Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 410:106-111.
12. Chandy KG, Cahalan M, Pennington M, Norton RS, Wulff H, and Gutman GA (2001) Potassium channels in T lymphocytes: toxins to therapeutic immunosuppressants. Toxicon 39:1269-1276.
13. Chauhan SS, Varshney A, Verma B, and Pennington MW (2007) Efficient synthesis of protected L-phosphonophenylalanine (Ppa) derivatives suitable for solid phase peptide synthesis. Tetrahedron Lett 48:4051-4054.
14. Chen R, Li L, and Weng Z (2003) ZDOCK: an initial-stage protein-docking algorithm. Proteins 52:80-87.
15. + T cells specific for respiratory viruses in the human lung. J Exp Med 202:1433-1442.
16. Domchek SM, Auger KR, Chatterjee S, Burke TR Jr, and Shoelson SE (1992) Inhibition of SH2 domain/phosphoprotein association by a nonhydrolyzable phos- phonopeptide. Biochemistry 31:9865-9870.
17. Ellis CN and Krueger GG (2001) Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 345:248 -255.
18. Fiser A and Sali A (2003) Modeller: generation and refinement of homology-based protein structure models. Methods Enzymol 374:461-491.
19. + channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol 45:1227-1234.
20. + T-effector memory cells in peripheral blood of patients with relapsing-remitting multiple sclerosis compared to healthy controls. J Neuroimmunol 183:168-174.
21. Herrmann T, Güntert P, and Wuthrich K (2002) Protein NMR structure determination with automated NOE assignment using the new software CANDID and the torsion angle dynamics algorithm DYANA. JMol Biol 319:209-227.
22. Hubbard SJ and Thornton JM (1993) NACCESS' Computer Program. Department of Biochemistry and Molecular Biology, University College, London.
23. 22, a potent Kv1.3-specific immunosuppressive polypeptide. J Biol Chem 273:32697-32707.
24. King DS, Fields CG, and Fields GB (1990) A cleavage method which minimizes side reactions following Fmoc solid phase peptide synthesis. Int J Pept Protein Res 36:255-266.
25. Kivisäkk P, Mahad DJ, Callahan MK, Sikora K, Trebst C, Tucky B, Wujek J, Ravid R, Staugaitis SM, Lassmann H, et al. (2004) Expression of CCR7 in multiple sclerosis: implications for CNS immunity. Ann Neurol 55:627-638.
26. + T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A 102:9571-9576.
27. Koradi R, Billeter M, and Wüthrich K (1996) MOLMOL: a program for display and analysis of macromolecular structures. J Mol Graph 14:51-55, 29 -32.
28. + memory T cells with high CD26 surface expression are enriched for Th1 markers and correlate with clinical severity of multiple sclerosis. J Neuroimmunol 181:157-164.
29. Laskowski RA, Rullmannn JA, MacArthur MW, Kaptein R, and Thornton JM (1996) AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J Biomol NMR 8:477-486.
30. Li L, Chen R, and Weng Z (2003) RDOCK: refinement of rigid-body protein docking predictions. Proteins 53:693-707.
31. Lindhal E, Hess B, and van der Spoel D (2001) GROMACS 3.0: a package for molecular simulation and trajectory analysis. J Mol Model 7:306 -317.
32. Liu WQ, Olszowy E, Bischoff L, and Garbay C (2002) Enantioselective synthesis of (2S)-2-(4-phosphonophenylmethyl)-3-amino propionic acid suitably protected for peptide synthesis. Tetrahedron Lett 43:1417-1419.
33. MacKerell AD, Brooks B, Brooks CL, Nilsson L, Roux B, Won Y and Karplus M (1998) CHARMM: the energy function and its parameterization with an overview of the program, in The Encyclopedia of Computational Chemistry (P. v. R. Schleyer, et al., eds) pp 271-277, John Wiley & Sons, Chichester, UK.
34. +CD28- costimulation-independent T cells in multiple sclerosis. J Clin Invest 108: 1185-1194.
35. Matheu MP, Beeton C, Garcia A, Chi V, Rangaraju S, Safrina O, Monaghan K, Uemura MI, Li D, Pal S, et al. (2008) In situ imaging of effector memory T cells during DTH and suppression by Kv1.3 channel block. Immunity 29:602-614.
36. Matsueda GR and Steward JM (1981) A p-methylbenzhydrylamine resin for improved solid-phase synthesis of peptide amides. Peptides 2:45-50.
37. Nomizu M, Otaka A, Burke TR, and Roller PP (1994) Synthesis of phosphonomethyl-phenylalanine and phosphotyrosine containing cyclic peptides as inhibitors of protein tyrosine kinanse/SH interactions. Tetrahedron 50:2691-2702.
38. Pennington M, Mahnir V, Khaytin I, Zaydenberg I, Byrnes M, and Kem W (1996a) An essential binding surface for ShK toxin interaction with rat brain potassium channels. Biochemistry 35:16407-16411.
39. Pennington M, Mahnir V, Krafte D, Zaydenberg I, Byrnes M, Khaytin I, Crowley K, and Kem W (1996b) Identification of three separate binding sites on SHK toxin, a potent inhibitor of voltage-dependent potassium channels in human T-lymphocytes and rat brain. Biochem Biophys Res Commun 219:696 -701.
40. Pennington MW, Lanigan MD, Kalman K, Mahnir VM, Rauer H, McVaugh CT, Behm D, Donaldson D, Chandy KG, Kem WR, et al. (1999) Role of disulfide bonds in the structure and potassium channel blocking activity of ShK toxin. Biochemistry 38:14549 -14558.
41. Pereira LE, Villinger F, Wulff H, Sankaranarayanan A, Raman G, and Ansari AA (2007) Pharmacokinetics, toxicity, and functional studies of the selective Kv1.3 channel blocker 5-(4-phenoxybutoxy)psoralen in rhesus macaques. Exp Biol Med(Maywood) 232:1338 -1354.
42. Pohl J, Hubalek F, Byrnes ME, Nielsen KR, Woods A, and Pennington MW (1995)Assignment of the three disulfide bonds in ShK toxin: a potent potassium channel inhibitor from the sea anemone Stichodactyla helianthus. Lett Peptide Sci 1:291297.
43. Rauer H, Pennington M, Cahalan M, and Chandy KG (1999) Structural conservation of the pores of calcium-activated and voltage-gated potassium channels determined by a sea anemone toxin. J Biol Chem 274:21885-21892.
44. Rus H, Pardo CA, Hu L, Darrah E, Cudrici C, Niculescu T, Niculescu F, Mullen KM, Allie R, Guo L, et al. (2005) The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci U S A 102:11094 -11099.
45. Schonland SO, Lopez C, Widmann T, Zimmer J, Bryl E, Goronzy JJ, and Weyand CM (2003) Premature telomeric loss in rheumatoid arthritis is genetically determined and involves both myeloid and lymphoid cell lineages. Proc Natl Acad Sci U S A 100:13471-13476.
46. Tudor JE, Pallaghy PK, Pennington MW, and Norton RS (1996) Solution structure of ShK toxin, a novel potassium channel inhibitor from a sea anemone. Nat Struct Biol 3:317-320.
47. Ulrich EL, Akutsu H, Doreleijers JF, Harano Y, Ioannidis YE, Lin J, Livny M, Mading S, Maziuk D, Miller Z, et al. (2007) BioMagResBank. Nucleic Acids Res 36:D402-D408.
48. Viglietta V, Kent SC, Orban T, and Hafler DA (2002) GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes. J Clin Invest 109:895903.
49. Wallace MS (2006) Ziconotide: a new nonopioid intrathecal analgesic for the treatment of chronic pain. Expert Rev Neurother 6:1423-1428.
50. + channel in effector memory T cells as new target for MS. J Clin Invest 111:1703-1713.
51. + T cells. J Immunol 172:2476-2486.
52. + channels in microglia. J Gen Physiol 111:781-794.